Cytek Biosciences Total Long Term Liabilities 2021-2025 | CTKB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cytek Biosciences total long term liabilities from 2021 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Cytek Biosciences Total Long Term Liabilities 2021-2025 | CTKB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Cytek Biosciences total long term liabilities from 2021 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$209.6B
Amgen (AMGN)	$149.1B
Gilead Sciences (GILD)	$130.2B
Vertex Pharmaceuticals (VRTX)	$125.6B
Bristol Myers Squibb (BMY)	$100.2B
CSL (CSLLY)	$74.3B
GSK (GSK)	$74.1B
Regeneron Pharmaceuticals (REGN)	$61.6B
Argenex SE (ARGX)	$36.2B
Alnylam Pharmaceuticals (ALNY)	$30.5B
BioNTech SE (BNTX)	$23.7B
BeiGene (ONC)	$22.8B
Biogen (BIIB)	$17.4B
Genmab (GMAB)	$13.3B
Genmab (GNMSF)	$13.3B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$11.3B
Illumina (ILMN)	$11.3B
Incyte (INCY)	$11.3B
Ascendis Pharma (ASND)	$10.1B
Exelixis (EXEL)	$10B
Swedish Orphan Biovitrum (BIOVF)	$9.6B
Moderna (MRNA)	$9.6B
QIAGEN (QGEN)	$9B
Exact Sciences (EXAS)	$7.7B
Bio-Techne Corp (TECH)	$7.6B
Repligen (RGEN)	$7.3B
Halozyme Therapeutics (HALO)	$7.3B
Roivant Sciences (ROIV)	$7.2B
Revolution Medicines (RVMD)	$6.8B